Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I1BQ
|
||||
| Former ID |
DCL000842
|
||||
| Drug Name |
IL-18BP
|
||||
| Indication | B-cell non-hodgkin's lymphoma; Rheumatoid arthritis [ICD9: 200, 202, 202.8, 710-719, 714; ICD10:C81-C86, C82-C85, M00-M25, M05-M06] | Discontinued in Phase 1 | [1] | ||
| Company |
Yeda; Merck Serono
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-18 | Target Info | Binder | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| NOD-like receptor signaling pathway | |||||
| Cytosolic DNA-sensing pathway | |||||
| Salmonella infection | |||||
| Legionellosis | |||||
| African trypanosomiasis | |||||
| Malaria | |||||
| Tuberculosis | |||||
| Influenza A | |||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Toll receptor signaling pathway | |||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| IL12-mediated signaling events | |||||
| IL23-mediated signaling events | |||||
| Cellular roles of Anthrax toxin | |||||
| IL12 signaling mediated by STAT4 | |||||
| Reactome | Interleukin-1 processing | ||||
| WikiPathways | Hypertrophy Model | ||||
| IL1 and megakaryotyces in obesity | |||||
| Corticotropin-releasing hormone | |||||
| NOD pathway | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013227) | ||||
| REF 2 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.